<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20241125195446&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20241125195446&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 26 Nov 2024 00:54:47 +0000</lastbuilddate>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585932/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):1812-1814. doi: 10.1161/CIRCULATIONAHA.124.072172. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585932/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39585932</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072172>10.1161/CIRCULATIONAHA.124.072172</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585932</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dongze Qin</dc:creator>
<dc:creator>Radheshyam Modanwal</dc:creator>
<dc:creator>Richard N Kitsis</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Extracellular Role for the Intracellular Cell Death Mediator RIPK3 in Myocardial Infarction</dc:title>
<dc:identifier>pmid:39585932</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072172</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585931/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):e467. doi: 10.1161/CIRCULATIONAHA.124.070129. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585931/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39585931</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070129>10.1161/CIRCULATIONAHA.124.070129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585931</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Meng Zhang</dc:creator>
<dc:creator>Xudong Pan</dc:creator>
<dc:creator>Xiaoyan Zhu</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era"</dc:title>
<dc:identifier>pmid:39585931</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070129</dc:identifier>
</item>
<item>
<title>Technologic Advances in Cardiac Electrophysiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):1745-1746. doi: 10.1161/CIRCULATIONAHA.124.071542. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39585930</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071542>10.1161/CIRCULATIONAHA.124.071542</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585930</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Augustus Grant</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Technologic Advances in Cardiac Electrophysiology</dc:title>
<dc:identifier>pmid:39585930</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071542</dc:identifier>
</item>
<item>
<title>Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 26;150(22):1815-1817. doi: 10.1161/CIRCULATIONAHA.124.070432. Epub 2024 Nov 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39585929</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070432>10.1161/CIRCULATIONAHA.124.070432</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585929</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Osnat Itzhaki Ben Zadok</dc:creator>
<dc:creator>Panagiotis Simitsis</dc:creator>
<dc:creator>Caron Jacobson</dc:creator>
<dc:creator>Omar Nadeem</dc:creator>
<dc:creator>Matthew J Frigault</dc:creator>
<dc:creator>Noopur Raje</dc:creator>
<dc:creator>Caitlyn Duffy</dc:creator>
<dc:creator>Patrick Costello</dc:creator>
<dc:creator>Jamie Dela Cruz</dc:creator>
<dc:creator>Andrew Looka</dc:creator>
<dc:creator>Anju Nohria</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy</dc:title>
<dc:identifier>pmid:39585929</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070432</dc:identifier>
</item>
<item>
<title>PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39585648/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Piezo1 deficiency aggravates MFS aneurysms by promoting TGF-β signalling pathway activation via TGF-β receptor 2 endocytosis and a decrease in autophagy. These data suggest that PIEZO1 may be a potential therapeutic target for MFS treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 25:ehae786. doi: 10.1093/eurheartj/ehae786. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Marfan syndrome (MFS) is a hereditary disorder primarily caused by mutations in the FBN1 gene. Its critical cardiovascular manifestation is thoracic aortic aneurysm (TAA), which poses life-threatening risks. Owing to the lack of effective pharmacological therapies, surgical intervention continues to be the current definitive treatment. In this study, the role of Piezo-type mechanosensitive ion channel component 1 (Piezo1) in MFS was investigated and the activation of PIEZO1 was identified as a potential treatment for MFS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PIEZO1 expression was detected in MFS mice (Fbn1C1041G/+) and patients. Piezo1 conditional knockout mice in vascular smooth muscle cells of MFS mice (MFS × CKO) was generated, and bioinformatics analysis and experiments in vitro and in vivo were performed to investigate the role of Piezo1 in MFS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: PIEZO1 expression decreased in the aortas of MFS mice; MFS × CKO mice showed aggravated TAA, inflammation, extracellular matrix remodelling, and TGF-β pathway activation compared to MFS mice. Mechanistically, PIEZO1 knockout exacerbated the activation of the TGF-β signalling pathway by inhibiting the endocytosis and autophagy of TGF-β receptor 2 mediated by Rab GTPase 3C. Additionally, the pharmacological activation PIEZO1 through Yoda1 prevented TGF-β signalling pathway activation and reversed TAA in MFS mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Piezo1 deficiency aggravates MFS aneurysms by promoting TGF-β signalling pathway activation via TGF-β receptor 2 endocytosis and a decrease in autophagy. These data suggest that PIEZO1 may be a potential therapeutic target for MFS treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39585648/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39585648</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae786>10.1093/eurheartj/ehae786</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39585648</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Peiwen Yang</dc:creator>
<dc:creator>Hao Liu</dc:creator>
<dc:creator>Shilin Wang</dc:creator>
<dc:creator>Xiaoyue Xiao</dc:creator>
<dc:creator>Lang Jiang</dc:creator>
<dc:creator>Sheng Le</dc:creator>
<dc:creator>Shanshan Chen</dc:creator>
<dc:creator>Ping Ye</dc:creator>
<dc:creator>Jiahong Xia</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2</dc:title>
<dc:identifier>pmid:39585648</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae786</dc:identifier>
</item>
<item>
<title>Loss of the Endothelial Glycocalyx Component EMCN Leads to Glomerular Impairment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39584795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: Our study demonstrates a critical role of the endothelial marker EMCN in supporting normal glomerular filtration barrier structure and function by maintaining glomerular endothelial tight junction and homeostasis and podocyte function through endothelial-podocyte crosstalk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Nov 25. doi: 10.1161/CIRCRESAHA.124.325218. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: EMCN (endomucin), an endothelial-specific glycocalyx component, was found to be highly expressed by the endothelium of the renal glomerulus. We reported an anti-inflammatory role of EMCN and its involvement in the regulation of VEGF (vascular endothelial growth factor) activity through modulating VEGFR2 (VEGF receptor 2) endocytosis. The goal of this study is to investigate the phenotypic and functional effects of EMCN deficiency using the first global EMCN knockout mouse model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Global EMCN knockout mice were generated by crossing EMCN-floxed mice with ROSA26-Cre mice. Flow cytometry was used to analyze infiltrating myeloid cells in the kidneys. The ultrastructure of the glomerular filtration barrier was examined by transmission electron microscopy, whereas urinary albumin, creatinine, and total protein levels were analyzed from freshly collected urine samples. Expression and localization of EMCN, EGFP, CD45, CD31, CD34, podocin, and albumin were examined by immunohistochemistry. Mice were weighed regularly, and their systemic blood pressure was measured using a noninvasive tail-cuff system. Glomerular endothelial cells and podocytes were isolated by fluorescence-activated cell sorting for RNA sequencing. Transcriptional profiles were analyzed to identify differentially expressed genes in both endothelium and podocytes, followed by gene ontology analysis. Protein levels of EMCN, albumin, and podocin were quantified by Western blot.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The EMCN<sup>-/-</sup> mice exhibited increased infiltration of CD45<sup>+</sup> cells, with an increased proportion of Ly6G<sup>high</sup>Ly6C<sup>high</sup> myeloid cells and higher VCAM-1 (vascular cell adhesion molecule 1) expression. EMCN<sup>-/-</sup> mice displayed albuminuria with increased albumin in the Bowman's space compared with the EMCN<sup>+/+</sup> littermates. Glomeruli in EMCN<sup>-/-</sup> mice revealed fused and effaced podocyte foot processes and disorganized endothelial fenestrations. We found no significant difference in blood pressure between EMCN knockout mice and their wild-type littermates. RNA sequencing of glomerular endothelial cells revealed downregulation of cell-cell adhesion and MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase) pathways, along with glycocalyx and extracellular matrix remodeling. In podocytes, we observed reduced VEGF signaling and alterations in cytoskeletal organization. Notably, there was a significant decrease in both mRNA and protein levels of podocin, a key component of the slit diaphragm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Our study demonstrates a critical role of the endothelial marker EMCN in supporting normal glomerular filtration barrier structure and function by maintaining glomerular endothelial tight junction and homeostasis and podocyte function through endothelial-podocyte crosstalk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39584795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39584795</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325218>10.1161/CIRCRESAHA.124.325218</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39584795</guid>
<pubDate>Mon, 25 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhengping Hu</dc:creator>
<dc:creator>Issahy Cano</dc:creator>
<dc:creator>Fengyang Lei</dc:creator>
<dc:creator>Jie Liu</dc:creator>
<dc:creator>Ramon Bossardi Ramos</dc:creator>
<dc:creator>Harper Gordon</dc:creator>
<dc:creator>Eleftherios I Paschalis</dc:creator>
<dc:creator>Magali Saint-Geniez</dc:creator>
<dc:creator>Yin Shan Eric Ng</dc:creator>
<dc:creator>Patricia A D'Amore</dc:creator>
<dc:date>2024-11-25</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Loss of the Endothelial Glycocalyx Component EMCN Leads to Glomerular Impairment</dc:title>
<dc:identifier>pmid:39584795</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325218</dc:identifier>
</item>
<item>
<title>Targeting fibroblast phenotype switching in cardiac remodelling as a promising antifibrotic strategy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39582108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>Myocardial fibrosis, a common feature of heart disease, remains an unsolved clinical challenge. Fibrosis resolution requires activation of cardiac fibroblasts exhibiting context-dependent beneficial and detrimental dichotomy. Here, we explored the hypothesis of fibroblast reversible transition between quiescence and activated myofibroblastic states as a manifestation of cell phenotypic switching in myocardial remodelling. In support, gene regulatory networks executing conversion of cardiac...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 25:ehae722. doi: 10.1093/eurheartj/ehae722. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Myocardial fibrosis, a common feature of heart disease, remains an unsolved clinical challenge. Fibrosis resolution requires activation of cardiac fibroblasts exhibiting context-dependent beneficial and detrimental dichotomy. Here, we explored the hypothesis of fibroblast reversible transition between quiescence and activated myofibroblastic states as a manifestation of cell phenotypic switching in myocardial remodelling. In support, gene regulatory networks executing conversion of cardiac fibroblasts to myofibroblasts and vice versa in fibrosis resolution are reconstructed using TRANSPATH database. In a scenario of fibroblast activation triggered by transforming growth factor β, a cardinal mediator of tissue fibrosis, signalling cascades governing entry into or exit from specific fibroblast statures in cardiac fibrotic remodelling were dissected. It is suggested that fibroblast phenotypic switching constitutes the central gait toward guiding cell state-gating strategies to counteract adverse cardiac fibrosis, a devastating disorder with no approved therapeutic option.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39582108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39582108</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae722>10.1093/eurheartj/ehae722</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39582108</guid>
<pubDate>Sun, 24 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Alexander Kel</dc:creator>
<dc:creator>Thomas Thum</dc:creator>
<dc:creator>Oksana Kunduzova</dc:creator>
<dc:date>2024-11-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Targeting fibroblast phenotype switching in cardiac remodelling as a promising antifibrotic strategy</dc:title>
<dc:identifier>pmid:39582108</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae722</dc:identifier>
</item>
<item>
<title>A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis: A Nationwide GAMES Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39580721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CoNSIE was a relatively common (18.4%) and life-threatening entity with particularities by species yet generally high rates of surgery and mortality, although its prognosis improved over time.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 25:S0735-1097(24)08573-5. doi: 10.1016/j.jacc.2024.09.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coagulase-negative staphylococci (CoNS) are an increasingly common cause of infective endocarditis (IE) and lack recent data from large studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Our aim was to describe the epidemiology, clinical characteristics, and outcomes of staphylococcal IE in a contemporary nationwide cohort study, while comparing coagulase-negative staphylococcal IE (CoNSIE) to IE from Staphylococcus aureus (SAIE), and among IE caused by Staphylococcus epidermidis (SE), S. lugdunensis (SL), and other CoNS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We completed a post hoc analysis of a prospectively collected cohort of 4,567 consecutive definitive IE episodes from 44 Spanish centers between 2008 and 2022 (GAMES ["Grupos de Apoyo al Manejo de la Endocarditis Infecciosa en España"] cohort). A total of 842 cases of CoNSIE were compared with 1,109 cases of SAIE. Additionally, 647 episodes caused by SE were compared with 54 caused by SL and 109 caused by 9 other known CoNS species. Multivariate analyses were performed to investigate prognostic factors for in-hospital and 1-year mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Staphylococci accounted for 1,951 (42.7%) episodes of IE. The predominant CoNS etiology was SE (76.8%), followed by SL (6.4%), S. capitis (3.5%), S. haemolyticus (3.2%), S. hominis (3.2%), S. warneri (1.5%), and 5 other species. CoNSIE showed a distinct clinical profile from SAIE (older age, higher rates of prior heart disease, aortic and prosthetic valve involvement, nosocomial acquisition, methicillin resistance, intracardiac complications, and cardiac surgery), while in-hospital mortality was higher in SAIE (32.8% vs 37.1%; P = 0.049), with no significant differences in 1-year mortality. S. lugdunensis displayed a shorter course of infection and higher rates of leaflet perforation/rupture than S. epidermidis and other CoNS, but cardiac surgery rates (60.4% vs 61.1% vs 56.0%; P = 0.850), as well as in-hospital (33.1% vs 37.0% vs 27.5%; P = 0.540) and 1-year mortality rates were high and similar in all groups. Septic shock, heart failure, and cardiac surgery (protective) were consistently identified as independent prognostic factors, whereas none of the staphylococcal species were independently associated with mortality. Last, each 5-year study period was independently associated with a reduction in staphylococcal in-hospital and 1-year mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CoNSIE was a relatively common (18.4%) and life-threatening entity with particularities by species yet generally high rates of surgery and mortality, although its prognosis improved over time.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39580721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39580721</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.027>10.1016/j.jacc.2024.09.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39580721</guid>
<pubDate>Sun, 24 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Clara Palom-Grau</dc:creator>
<dc:creator>Guillermo Cuervo</dc:creator>
<dc:creator>Patricia Muñoz</dc:creator>
<dc:creator>Mercedes Marín Arriaza</dc:creator>
<dc:creator>Manuel Martínez-Sellés</dc:creator>
<dc:creator>Víctor González-Ramallo</dc:creator>
<dc:creator>Arístides de Alarcón</dc:creator>
<dc:creator>Manuel Poyato-Borrego</dc:creator>
<dc:creator>Raquel Rodríguez-García</dc:creator>
<dc:creator>M Ángeles Rodríguez-Esteban</dc:creator>
<dc:creator>M Carmen Fariñas</dc:creator>
<dc:creator>Claudia González-Rico</dc:creator>
<dc:creator>Miguel Ángel Goenaga</dc:creator>
<dc:creator>Guillermo Ojeda-Burgos</dc:creator>
<dc:creator>Ane Josune Goikoetxea-Agirre</dc:creator>
<dc:creator>Jorge Calderón-Parra</dc:creator>
<dc:creator>Juan Carlos López-Azor</dc:creator>
<dc:creator>Elisa García-Vázquez</dc:creator>
<dc:creator>Belén Loeches</dc:creator>
<dc:creator>Eduard Quintana</dc:creator>
<dc:creator>Cristina García de la Mària</dc:creator>
<dc:creator>Jaume Llopis</dc:creator>
<dc:creator>José M Miró</dc:creator>
<dc:creator>GAMES Investigators</dc:creator>
<dc:date>2024-11-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis: A Nationwide GAMES Cohort Study</dc:title>
<dc:identifier>pmid:39580721</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.027</dc:identifier>
</item>
<item>
<title>CoN(S) Nuevas Perspectivas: Insights Into Coagulase-Negative Staphylococcal Infective Endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39580720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10421-4. doi: 10.1016/j.jacc.2024.10.110. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39580720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39580720</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.110>10.1016/j.jacc.2024.10.110</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39580720</guid>
<pubDate>Sun, 24 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Supavit Chesdachai</dc:creator>
<dc:creator>Daniel C DeSimone</dc:creator>
<dc:creator>Larry M Baddour</dc:creator>
<dc:date>2024-11-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>CoN(S) Nuevas Perspectivas: Insights Into Coagulase-Negative Staphylococcal Infective Endocarditis</dc:title>
<dc:identifier>pmid:39580720</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.110</dc:identifier>
</item>
<item>
<title>Transcatheter Tricuspid Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39580719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>Transcatheter tricuspid valve replacement (TTVR) has emerged as a promising intervention for the treatment of severe tricuspid regurgitation with complex valve morphology. This consensus document provides a comprehensive overview of the current state of orthotopic TTVR, focusing on patient selection, procedural details, and follow-up care. Clinical outcomes from initial studies and compassionate use cases are discussed, highlighting the effectiveness of TTVR in reducing tricuspid regurgitation,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 23:S0735-1097(24)09961-3. doi: 10.1016/j.jacc.2024.10.071. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcatheter tricuspid valve replacement (TTVR) has emerged as a promising intervention for the treatment of severe tricuspid regurgitation with complex valve morphology. This consensus document provides a comprehensive overview of the current state of orthotopic TTVR, focusing on patient selection, procedural details, and follow-up care. Clinical outcomes from initial studies and compassionate use cases are discussed, highlighting the effectiveness of TTVR in reducing tricuspid regurgitation, inducing reverse right ventricular remodeling, and enhancing patients' quality of life. This review paper also addresses potential complications and challenges associated with TTVR, such as new-onset conduction disturbances, bleeding complications, and afterload mismatch, and provides expert recommendations for the periprocedural management, anticoagulation strategies, and long-term follow-up. With the commercial approval of the first TTVR system in the United States and Europe, it intends to serve as a reference for clinicians and researchers involved in the evolving field of transcatheter tricuspid valve interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39580719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39580719</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.071>10.1016/j.jacc.2024.10.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39580719</guid>
<pubDate>Sun, 24 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Rebecca Hahn</dc:creator>
<dc:creator>Rodrigo Estévez-Loureiro</dc:creator>
<dc:creator>Charles Davidson</dc:creator>
<dc:creator>Firas Zahr</dc:creator>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Anson Cheung</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Neil Fam</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:date>2024-11-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Tricuspid Valve Replacement</dc:title>
<dc:identifier>pmid:39580719</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.071</dc:identifier>
</item>
<item>
<title>Atlas of the plasma proteome in health and disease in 53,026 adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39579765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>Large-scale proteomics studies can refine our understanding of health and disease and enable precision medicine. Here, we provide a detailed atlas of 2,920 plasma proteins linking to diseases (406 prevalent and 660 incident) and 986 health-related traits in 53,026 individuals (median follow-up: 14.8 years) from the UK Biobank, representing the most comprehensive proteome profiles to date. This atlas revealed 168,100 protein-disease associations and 554,488 protein-trait associations. Over 650...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 15:S0092-8674(24)01268-6. doi: 10.1016/j.cell.2024.10.045. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Large-scale proteomics studies can refine our understanding of health and disease and enable precision medicine. Here, we provide a detailed atlas of 2,920 plasma proteins linking to diseases (406 prevalent and 660 incident) and 986 health-related traits in 53,026 individuals (median follow-up: 14.8 years) from the UK Biobank, representing the most comprehensive proteome profiles to date. This atlas revealed 168,100 protein-disease associations and 554,488 protein-trait associations. Over 650 proteins were shared among at least 50 diseases, and over 1,000 showed sex and age heterogeneity. Furthermore, proteins demonstrated promising potential in disease discrimination (area under the curve [AUC] >; 0.80 in 183 diseases). Finally, integrating protein quantitative trait locus data determined 474 causal proteins, providing 37 drug-repurposing opportunities and 26 promising targets with favorable safety profiles. These results provide an open-access comprehensive proteome-phenome resource (https://proteome-phenome-atlas.com/) to help elucidate the biological mechanisms of diseases and accelerate the development of disease biomarkers, prediction models, and therapeutic targets.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39579765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39579765</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.045>10.1016/j.cell.2024.10.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39579765</guid>
<pubDate>Sat, 23 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yue-Ting Deng</dc:creator>
<dc:creator>Jia You</dc:creator>
<dc:creator>Yu He</dc:creator>
<dc:creator>Yi Zhang</dc:creator>
<dc:creator>Hai-Yun Li</dc:creator>
<dc:creator>Xin-Rui Wu</dc:creator>
<dc:creator>Ji-Yun Cheng</dc:creator>
<dc:creator>Yu Guo</dc:creator>
<dc:creator>Zi-Wen Long</dc:creator>
<dc:creator>Yi-Lin Chen</dc:creator>
<dc:creator>Ze-Yu Li</dc:creator>
<dc:creator>Liu Yang</dc:creator>
<dc:creator>Ya-Ru Zhang</dc:creator>
<dc:creator>Shi-Dong Chen</dc:creator>
<dc:creator>Yi-Jun Ge</dc:creator>
<dc:creator>Yu-Yuan Huang</dc:creator>
<dc:creator>Le-Ming Shi</dc:creator>
<dc:creator>Qiang Dong</dc:creator>
<dc:creator>Ying Mao</dc:creator>
<dc:creator>Jian-Feng Feng</dc:creator>
<dc:creator>Wei Cheng</dc:creator>
<dc:creator>Jin-Tai Yu</dc:creator>
<dc:date>2024-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Atlas of the plasma proteome in health and disease in 53,026 adults</dc:title>
<dc:identifier>pmid:39579765</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.045</dc:identifier>
</item>
<item>
<title>snoRNA-facilitated protein secretion revealed by transcriptome-wide snoRNA target identification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39579764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>Small nucleolar RNAs (snoRNAs) are non-coding RNAs known for guiding RNA modifications, including 2'-O-methylation (N(m)) and pseudouridine (Ψ). While snoRNAs may also interact with other RNAs, such as mRNA, the full repertoire of RNAs targeted by snoRNA remains elusive due to the lack of effective technologies that identify snoRNA targets transcriptome wide. Here, we develop a chemical crosslinking-based approach that comprehensively detects cellular RNA targets of snoRNAs, yielding thousands...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 21:S0092-8674(24)01269-8. doi: 10.1016/j.cell.2024.10.046. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Small nucleolar RNAs (snoRNAs) are non-coding RNAs known for guiding RNA modifications, including 2'-O-methylation (N<sub>m</sub>) and pseudouridine (Ψ). While snoRNAs may also interact with other RNAs, such as mRNA, the full repertoire of RNAs targeted by snoRNA remains elusive due to the lack of effective technologies that identify snoRNA targets transcriptome wide. Here, we develop a chemical crosslinking-based approach that comprehensively detects cellular RNA targets of snoRNAs, yielding thousands of previously unrecognized snoRNA-mRNA interactions in human cells and mouse brain tissues. Many interactions occur outside of snoRNA-guided RNA modification sites, hinting at non-canonical functions beyond RNA modification. We find that one of these snoRNAs, SNORA73, targets mRNAs that encode secretory proteins and membrane proteins. SNORA73 also interacts with 7SL RNA, part of the signal recognition particle (SRP) required for protein secretion. The mRNA-SNORA73-7SL RNA interactions enhance the association of the SNORA73-target mRNAs with SRP, thereby facilitating the secretion of encoded proteins.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39579764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39579764</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.046>10.1016/j.cell.2024.10.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39579764</guid>
<pubDate>Sat, 23 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Bei Liu</dc:creator>
<dc:creator>Tong Wu</dc:creator>
<dc:creator>Bernadette A Miao</dc:creator>
<dc:creator>Fei Ji</dc:creator>
<dc:creator>Shun Liu</dc:creator>
<dc:creator>Pingluan Wang</dc:creator>
<dc:creator>Yutao Zhao</dc:creator>
<dc:creator>Yuhao Zhong</dc:creator>
<dc:creator>Arunkumar Sundaram</dc:creator>
<dc:creator>Tie-Bo Zeng</dc:creator>
<dc:creator>Marta Majcherska-Agrawal</dc:creator>
<dc:creator>Robert J Keenan</dc:creator>
<dc:creator>Tao Pan</dc:creator>
<dc:creator>Chuan He</dc:creator>
<dc:date>2024-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>snoRNA-facilitated protein secretion revealed by transcriptome-wide snoRNA target identification</dc:title>
<dc:identifier>pmid:39579764</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.046</dc:identifier>
</item>
<item>
<title>Exercise training in long COVID: the EXER-COVID trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39575513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 22:ehae721. doi: 10.1093/eurheartj/ehae721. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39575513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39575513</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae721>10.1093/eurheartj/ehae721</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39575513</guid>
<pubDate>Fri, 22 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Robinson Ramírez-Vélez</dc:creator>
<dc:creator>Julio Oteiza</dc:creator>
<dc:creator>Gaizka Legarra-Gorgoñon</dc:creator>
<dc:creator>Sergio Oscoz-Ochandorena</dc:creator>
<dc:creator>Nora García-Alonso</dc:creator>
<dc:creator>Yesenia García-Alonso</dc:creator>
<dc:creator>María Correa-Rodríguez</dc:creator>
<dc:creator>Adrian Soto-Mota</dc:creator>
<dc:creator>Mikel Izquierdo</dc:creator>
<dc:date>2024-11-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exercise training in long COVID: the EXER-COVID trial</dc:title>
<dc:identifier>pmid:39575513</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae721</dc:identifier>
</item>
<item>
<title>Evolutionary genomics of the emergence of brown algae as key components of coastal ecosystems</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39571576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>Brown seaweeds are keystone species of coastal ecosystems, often forming extensive underwater forests, and are under considerable threat from climate change. In this study, analysis of multiple genomes has provided insights across the entire evolutionary history of this lineage, from initial emergence, through later diversification of the brown algal orders, down to microevolutionary events at the genus level. Emergence of the brown algal lineage was associated with a marked gain of new...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 18:S0092-8674(24)01272-8. doi: 10.1016/j.cell.2024.10.049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Brown seaweeds are keystone species of coastal ecosystems, often forming extensive underwater forests, and are under considerable threat from climate change. In this study, analysis of multiple genomes has provided insights across the entire evolutionary history of this lineage, from initial emergence, through later diversification of the brown algal orders, down to microevolutionary events at the genus level. Emergence of the brown algal lineage was associated with a marked gain of new orthologous gene families, enhanced protein domain rearrangement, increased horizontal gene transfer events, and the acquisition of novel signaling molecules and key metabolic pathways, the latter notably related to biosynthesis of the alginate-based extracellular matrix, and halogen and phlorotannin biosynthesis. We show that brown algal genome diversification is tightly linked to phenotypic divergence, including changes in life cycle strategy and zoid flagellar structure. The study also showed that integration of large viral genomes has had a significant impact on brown algal genome content throughout the emergence of the lineage.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39571576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39571576</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.049>10.1016/j.cell.2024.10.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39571576</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>France Denoeud</dc:creator>
<dc:creator>Olivier Godfroy</dc:creator>
<dc:creator>Corinne Cruaud</dc:creator>
<dc:creator>Svenja Heesch</dc:creator>
<dc:creator>Zofia Nehr</dc:creator>
<dc:creator>Nachida Tadrent</dc:creator>
<dc:creator>Arnaud Couloux</dc:creator>
<dc:creator>Loraine Brillet-Guéguen</dc:creator>
<dc:creator>Ludovic Delage</dc:creator>
<dc:creator>Dean Mckeown</dc:creator>
<dc:creator>Taizo Motomura</dc:creator>
<dc:creator>Duncan Sussfeld</dc:creator>
<dc:creator>Xiao Fan</dc:creator>
<dc:creator>Lisa Mazéas</dc:creator>
<dc:creator>Nicolas Terrapon</dc:creator>
<dc:creator>Josué Barrera-Redondo</dc:creator>
<dc:creator>Romy Petroll</dc:creator>
<dc:creator>Lauric Reynes</dc:creator>
<dc:creator>Seok-Wan Choi</dc:creator>
<dc:creator>Jihoon Jo</dc:creator>
<dc:creator>Kavitha Uthanumallian</dc:creator>
<dc:creator>Kenny Bogaert</dc:creator>
<dc:creator>Céline Duc</dc:creator>
<dc:creator>Pélagie Ratchinski</dc:creator>
<dc:creator>Agnieszka Lipinska</dc:creator>
<dc:creator>Benjamin Noel</dc:creator>
<dc:creator>Eleanor A Murphy</dc:creator>
<dc:creator>Martin Lohr</dc:creator>
<dc:creator>Ananya Khatei</dc:creator>
<dc:creator>Pauline Hamon-Giraud</dc:creator>
<dc:creator>Christophe Vieira</dc:creator>
<dc:creator>Komlan Avia</dc:creator>
<dc:creator>Svea Sanja Akerfors</dc:creator>
<dc:creator>Shingo Akita</dc:creator>
<dc:creator>Yacine Badis</dc:creator>
<dc:creator>Tristan Barbeyron</dc:creator>
<dc:creator>Arnaud Belcour</dc:creator>
<dc:creator>Wahiba Berrabah</dc:creator>
<dc:creator>Samuel Blanquart</dc:creator>
<dc:creator>Ahlem Bouguerba-Collin</dc:creator>
<dc:creator>Trevor Bringloe</dc:creator>
<dc:creator>Rose Ann Cattolico</dc:creator>
<dc:creator>Alexandre Cormier</dc:creator>
<dc:creator>Helena Cruz de Carvalho</dc:creator>
<dc:creator>Romain Dallet</dc:creator>
<dc:creator>Olivier De Clerck</dc:creator>
<dc:creator>Ahmed Debit</dc:creator>
<dc:creator>Erwan Denis</dc:creator>
<dc:creator>Christophe Destombe</dc:creator>
<dc:creator>Erica Dinatale</dc:creator>
<dc:creator>Simon Dittami</dc:creator>
<dc:creator>Elodie Drula</dc:creator>
<dc:creator>Sylvain Faugeron</dc:creator>
<dc:creator>Jeanne Got</dc:creator>
<dc:creator>Louis Graf</dc:creator>
<dc:creator>Agnès Groisillier</dc:creator>
<dc:creator>Marie-Laure Guillemin</dc:creator>
<dc:creator>Lars Harms</dc:creator>
<dc:creator>William John Hatchett</dc:creator>
<dc:creator>Bernard Henrissat</dc:creator>
<dc:creator>Galice Hoarau</dc:creator>
<dc:creator>Chloé Jollivet</dc:creator>
<dc:creator>Alexander Jueterbock</dc:creator>
<dc:creator>Ehsan Kayal</dc:creator>
<dc:creator>Andrew H Knoll</dc:creator>
<dc:creator>Kazuhiro Kogame</dc:creator>
<dc:creator>Arthur Le Bars</dc:creator>
<dc:creator>Catherine Leblanc</dc:creator>
<dc:creator>Line Le Gall</dc:creator>
<dc:creator>Ronja Ley</dc:creator>
<dc:creator>Xi Liu</dc:creator>
<dc:creator>Steven T LoDuca</dc:creator>
<dc:creator>Pascal Jean Lopez</dc:creator>
<dc:creator>Philippe Lopez</dc:creator>
<dc:creator>Eric Manirakiza</dc:creator>
<dc:creator>Karine Massau</dc:creator>
<dc:creator>Stéphane Mauger</dc:creator>
<dc:creator>Laetitia Mest</dc:creator>
<dc:creator>Gurvan Michel</dc:creator>
<dc:creator>Catia Monteiro</dc:creator>
<dc:creator>Chikako Nagasato</dc:creator>
<dc:creator>Delphine Nègre</dc:creator>
<dc:creator>Eric Pelletier</dc:creator>
<dc:creator>Naomi Phillips</dc:creator>
<dc:creator>Philippe Potin</dc:creator>
<dc:creator>Stefan A Rensing</dc:creator>
<dc:creator>Ellyn Rousselot</dc:creator>
<dc:creator>Sylvie Rousvoal</dc:creator>
<dc:creator>Declan Schroeder</dc:creator>
<dc:creator>Delphine Scornet</dc:creator>
<dc:creator>Anne Siegel</dc:creator>
<dc:creator>Leila Tirichine</dc:creator>
<dc:creator>Thierry Tonon</dc:creator>
<dc:creator>Klaus Valentin</dc:creator>
<dc:creator>Heroen Verbruggen</dc:creator>
<dc:creator>Florian Weinberger</dc:creator>
<dc:creator>Glen Wheeler</dc:creator>
<dc:creator>Hiroshi Kawai</dc:creator>
<dc:creator>Akira F Peters</dc:creator>
<dc:creator>Hwan Su Yoon</dc:creator>
<dc:creator>Cécile Hervé</dc:creator>
<dc:creator>Naihao Ye</dc:creator>
<dc:creator>Eric Bapteste</dc:creator>
<dc:creator>Myriam Valero</dc:creator>
<dc:creator>Gabriel V Markov</dc:creator>
<dc:creator>Erwan Corre</dc:creator>
<dc:creator>Susana M Coelho</dc:creator>
<dc:creator>Patrick Wincker</dc:creator>
<dc:creator>Jean-Marc Aury</dc:creator>
<dc:creator>J Mark Cock</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Evolutionary genomics of the emergence of brown algae as key components of coastal ecosystems</dc:title>
<dc:identifier>pmid:39571576</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.049</dc:identifier>
</item>
<item>
<title>Advanced Imaging Assessment of the Impact of Tricuspid Regurgitation on Cardiac Remodeling: The TRILUMINATE Pivotal Imaging Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Advanced imaging from the TRILUMINATE Pivotal imaging substudy demonstrated that TriClip effectively reduced TR. Significant cardiac remodeling was observed at 30 days and sustained at 1 year. With TriClip, the extent of cardiac remodeling was associated with the degree of TR reduction. (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal; NCT03904147).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 30:S0735-1097(24)08459-6. doi: 10.1016/j.jacc.2024.09.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The impact of tricuspid regurgitation (TR) on cardiac remodeling has not been thoroughly studied in a randomized controlled trial using advanced imaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this analysis was to provide comparative longitudinal changes in right heart remodeling using cardiac magnetic resonance and time-resolved functional computed tomography (4D-CT) in patients with symptomatic severe TR randomized to TriClip vs medical therapy (control).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: TRILUMINATE Pivotal (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal) is an international randomized controlled trial in symptomatic patients with severe TR. A prospective imaging substudy was performed on TRILUMINATE Pivotal subjects at 10 sites. Cardiac magnetic resonance and 4D-CT were performed following dedicated imaging protocols at baseline and at 30 days, and a final 4D-CT at 1 year (all assessed by an imaging core lab).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Sixty-nine randomized subjects (31 TriClip, 38 control) were enrolled. TR volume significantly decreased with TriClip at 30 days (P &lt; 0.0001; 70% reduction). A strong association (r = 0.90; P &lt; 0.0001) was observed between changes in TR volume and right ventricular end-diastolic volume at 30 days. Significant reductions in right ventricular end-diastolic volume (12% reduction; P &lt; 0.001) and tricuspid annular area (11% reduction; P &lt; 0.0001) were seen at 30 days and sustained through 1 year with TriClip. No meaningful changes were observed in the control group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Advanced imaging from the TRILUMINATE Pivotal imaging substudy demonstrated that TriClip effectively reduced TR. Significant cardiac remodeling was observed at 30 days and sustained at 1 year. With TriClip, the extent of cardiac remodeling was associated with the degree of TR reduction. (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal; NCT03904147).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39570246</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.009>10.1016/j.jacc.2024.09.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570246</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>Markus Scherer</dc:creator>
<dc:creator>Miho Fukui</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>Serge Harb</dc:creator>
<dc:creator>Amit Pursnani</dc:creator>
<dc:creator>Jonathan G Schwartz</dc:creator>
<dc:creator>Samir Kapadia</dc:creator>
<dc:creator>Mark J Ricciardi</dc:creator>
<dc:creator>Omar Khalique</dc:creator>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>Dipan Shah</dc:creator>
<dc:creator>Steven H Little</dc:creator>
<dc:creator>Nishant Sekaran</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Peter Flueckiger</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Abbas Emaminia</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Zexu Lin</dc:creator>
<dc:creator>Phillip M Trusty</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>David Adams</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advanced Imaging Assessment of the Impact of Tricuspid Regurgitation on Cardiac Remodeling: The TRILUMINATE Pivotal Imaging Substudy</dc:title>
<dc:identifier>pmid:39570246</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.009</dc:identifier>
</item>
<item>
<title>Anatomic and Physiologic Repair of Congenitally Corrected Transposition of the Great Arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Anatomic repair of ccTGA patients results in higher overall and reintervention-free survival compared to physiologic repair. Specifically, patients who had anatomic repair at &lt;5 years of age or who had preoperative pulmonary artery banding have better survival.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 14:S0735-1097(24)09770-5. doi: 10.1016/j.jacc.2024.07.056. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Congenitally corrected transposition of the great arteries (ccTGA) is a rare cardiac anomaly. The management strategy historically consisted of physiologic repair, leaving the morphologic right ventricle to support the systemic circulation. More recently, anatomic repair has been implemented to bring the left ventricle into the systemic circulation. Uncertainty persists about which repair strategy has the best outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This meta-analysis aimed to summarize the long-term mortality risks following anatomic and physiologic repair of ccTGA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PubMed, Embase, and the Cochrane Database were searched. Data were extracted using prespecified data forms. The primary outcome was the composite risk of all-cause mortality or heart transplantation during hospitalization and at 1, 5, and 10 years of follow-up. Secondary outcomes included reintervention risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-seven studies totaling 2,844 patients were included. The incidence risk of mortality at 10 years was 11.7% (95% CI: 8.5%-15.3%) and 17.4% (95% CI: 12.4%-23.0%) in the anatomic and physiologic repair groups, respectively. The incidence risk of reintervention at 10 years was 24.5% (95% CI: 19.2%-30.1%) and 30.3% (95% CI: 23.5%-37.6%), respectively. The primary outcome was significantly lower at 10 years in anatomically repaired patients who had surgery at &lt;5 years of age and who had preoperative pulmonary artery banding (P<sub>heterogeneity</sub> &lt; 0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Anatomic repair of ccTGA patients results in higher overall and reintervention-free survival compared to physiologic repair. Specifically, patients who had anatomic repair at &lt;5 years of age or who had preoperative pulmonary artery banding have better survival.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39570245</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.056>10.1016/j.jacc.2024.07.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570245</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Kirolos A Jacob</dc:creator>
<dc:creator>Jürgen Hörer</dc:creator>
<dc:creator>Viktor Hraska</dc:creator>
<dc:creator>Valirie N Agbor</dc:creator>
<dc:creator>Saniyé Duchateau</dc:creator>
<dc:creator>Abraham van Wijk</dc:creator>
<dc:creator>David J Barron</dc:creator>
<dc:creator>Paul H Schoof</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anatomic and Physiologic Repair of Congenitally Corrected Transposition of the Great Arteries</dc:title>
<dc:identifier>pmid:39570245</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.056</dc:identifier>
</item>
<item>
<title>Getting Imaging Right: Multimodal Assessment of Right-Sided Heart Function in Patients Undergoing Tricuspid Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 14:S0735-1097(24)10030-7. doi: 10.1016/j.jacc.2024.10.077. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39570244</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.077>10.1016/j.jacc.2024.10.077</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570244</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mathias Orban</dc:creator>
<dc:creator>Nicole Karam</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Getting Imaging Right: Multimodal Assessment of Right-Sided Heart Function in Patients Undergoing Tricuspid Repair</dc:title>
<dc:identifier>pmid:39570244</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.077</dc:identifier>
</item>
<item>
<title>Congenitally Corrected Transposition of the Great Arteries: The Impact of Anatomic vs Physiologic Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 25:S0735-1097(24)09769-9. doi: 10.1016/j.jacc.2024.07.055. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39570243</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.055>10.1016/j.jacc.2024.07.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570243</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tara Karamlou</dc:creator>
<dc:creator>Justin Robinson</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Congenitally Corrected Transposition of the Great Arteries: The Impact of Anatomic vs Physiologic Repair</dc:title>
<dc:identifier>pmid:39570243</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.055</dc:identifier>
</item>
<item>
<title>5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The 5-year outcomes from the largest randomized LAAO clinical trial demonstrated the long-term safety and effectiveness of the Amulet occluder and Watchman 2.5 devices. The dual-seal Amulet occluder reduces atrial fibrillation-related thromboembolic events while eliminating the need for long-term OAC. (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial [Amulet IDE trial]; NCT02879448).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 15:S0735-1097(24)10313-0. doi: 10.1016/j.jacc.2024.10.101. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Amulet IDE trial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial) evaluated the safety and effectiveness of the Amulet occluder (Abbott) in patients with nonvalvular atrial fibrillation. The Amulet IDE trial is the largest randomized LAAO trial, comparing the Amulet occluder with the Watchman 2.5 device (Boston Scientific).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This analysis presents the 5-year results from the trial comparing the 2 devices head to head.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients enrolled in the Amulet IDE trial were at a high risk of stroke or systemic embolism defined as a CHADS2 score ≥2 or CHA2DS2-VASc score ≥3. Oral anticoagulation (OAC) use and key clinical outcomes are presented through 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,878 patients were randomized, with 1,833 undergoing a device implantation attempt (n = 917, Amulet occluder; and n = 916, Watchman device). A significantly higher percentage of patients were free of OAC in the Amulet occluder group at each follow-up visit, with 94.0% and 90.9% free of OAC at the last 5-year follow-up visit in the Amulet and Watchman device groups, respectively (P = 0.009). The 5-year clinical outcomes were similar between the Amulet and Watchman devices, including the composite of ischemic stroke or systemic embolism (7.4% vs 7.1%; P = 0.851), the composite of stroke, systemic embolism, or cardiovascular death (20.3% vs 20.7%; P = 0.666), major bleeding (20.1% vs 20.0%; P = 0.882), cardiovascular (CV) death (14.3% vs 15.4%; P = 0.429), and all-cause death (28.7% vs 31.1%; P = 0.217). Annualized ischemic stroke rates at 5 years were low and the same for Amulet (1.6%/y) and Watchman (1.6%/y) devices. Strokes in patients with the Amulet occluder were less severe (n = 38, nondisabling; n = 11, disabling; n = 11, fatal; n = 12, unknown) than strokes in patients with the Watchman device (n = 19, nondisabling; n = 22, disabling; n = 17, fatal; n = 10, unknown). Moreover, device factors (device-related thrombus or peridevice leak ≥3 mm) preceded stroke events and CV deaths more frequently in patients with the Watchman device (n = 63) compared with patients with the Amulet occluder (n = 31).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The 5-year outcomes from the largest randomized LAAO clinical trial demonstrated the long-term safety and effectiveness of the Amulet occluder and Watchman 2.5 devices. The dual-seal Amulet occluder reduces atrial fibrillation-related thromboembolic events while eliminating the need for long-term OAC. (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial [Amulet IDE trial]; NCT02879448).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39570242</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.101>10.1016/j.jacc.2024.10.101</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570242</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dhanunjaya Lakkireddy</dc:creator>
<dc:creator>Christopher R Ellis</dc:creator>
<dc:creator>David Thaler</dc:creator>
<dc:creator>Vijendra Swarup</dc:creator>
<dc:creator>Alok Gambhir</dc:creator>
<dc:creator>James Hermiller</dc:creator>
<dc:creator>Jens Erik Nielsen-Kudsk</dc:creator>
<dc:creator>Stephen Worthley</dc:creator>
<dc:creator>Devi Nair</dc:creator>
<dc:creator>Boris Schmidt</dc:creator>
<dc:creator>Rodney Horton</dc:creator>
<dc:creator>Nigel Gupta</dc:creator>
<dc:creator>Jordan A Anderson</dc:creator>
<dc:creator>Hong Zhao</dc:creator>
<dc:creator>Mohamad Alkhouli</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39570242</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.101</dc:identifier>
</item>
<item>
<title>Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570241/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The RF-SLAM algorithm accurately predicted all-cause mortality and death/HF hospitalization at 3 months and 1 year during the first 5 years of device implant, demonstrating good internal and external validity. Prospective studies and randomized trials are needed to evaluate model performance in other populations and settings and to determine its impact on patient outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08455-9. doi: 10.1016/j.jacc.2024.09.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Predicting the clinical trajectory of individual patients with implantable cardioverter-defibrillators (ICDs) is essential to inform clinical care. Machine learning approaches can potentially overcome the limitations of conventional statistical methods and provide more accurate, personalized risk estimates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We sought to develop and externally validate a novel machine learning algorithm for predicting all-cause mortality and/or heart failure (HF) hospitalization in ICD patients with and without cardiac resynchronization therapy (CRT) using variables that are readily available to treating clinicians. We also sought to identify key factors that separate patients along a continuum of risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Random forest for survival, longitudinal, and multivariate (RF-SLAM) data analysis was applied to predict 3-month and 1-year risks for all-cause mortality and a composite outcome of death/HF hospitalization during the first 5 years of device implant. Models were trained using a nationwide cohort from the Veterans Health Administration. Three models were sequentially tested, and external validation was performed in a separate nonveteran clinical registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The training and validation cohorts included 12,043 patients (age 67.5 ± 9.4 years) and 1,394 patients (age 66.3 ± 11.9 years), respectively. Median follow-up was 3.3 years for the training cohort and 3.6 years for validation cohort. The most accurate models for both outcomes included baseline demographics entered at the time of ICD implant (age, sex, CRT therapy) and time-varying ICD data with area under the receiver-operating characteristic curve for predicting death at 3 months (0.91; 95% CI: 0.87-0.94) and 1 year (0.80; 95% CI: 0.78-0.82); death/HF hospitalization at 3 months (0.81; 95% CI: 0.79-0.83) and 1 year (0.71; 95% CI: 0.70-0.72). Models demonstrated high discrimination and good calibration in the validation cohort. Additionally, time-varying physiologic data from ICDs, especially daily physical activity, had substantial importance in predicting outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The RF-SLAM algorithm accurately predicted all-cause mortality and death/HF hospitalization at 3 months and 1 year during the first 5 years of device implant, demonstrating good internal and external validity. Prospective studies and randomized trials are needed to evaluate model performance in other populations and settings and to determine its impact on patient outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570241/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39570241</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.006>10.1016/j.jacc.2024.09.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570241</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lindsey Rosman</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Kaicheng Wang</dc:creator>
<dc:creator>Anil K Gehi</dc:creator>
<dc:creator>James Dziura</dc:creator>
<dc:creator>Elena Salmoirago-Blotcher</dc:creator>
<dc:creator>Cynthia Brandt</dc:creator>
<dc:creator>Samuel F Sears</dc:creator>
<dc:creator>Matthew Burg</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators</dc:title>
<dc:identifier>pmid:39570241</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.006</dc:identifier>
</item>
<item>
<title>Adding AI to the Toolkit for Patients With Implantable Cardioverter-Defibrillators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241125195446&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 13:S0735-1097(24)09962-5. doi: 10.1016/j.jacc.2024.10.072. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241125195446&v=2.18.0.post9+e462414">39570240</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.072>10.1016/j.jacc.2024.10.072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570240</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Archana Ramireddy</dc:creator>
<dc:creator>Eric D Braunstein</dc:creator>
<dc:creator>Sumeet S Chugh</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Adding AI to the Toolkit for Patients With Implantable Cardioverter-Defibrillators</dc:title>
<dc:identifier>pmid:39570240</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.072</dc:identifier>
</item>





























</channel>
</rss>